Skip To Main Content
Gregory Barnsley on Muck Rack

Gregory Barnsley

As seen in: Nature, PLOS, The Lancet, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gregory

Contact Gregory, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Azithromycin mass drug administration to reduce childhood mortality in humanitarian crises

|
By Gregory Barnsley, Matthew E. Coldiron, Médecins Sans Frontières
| PLOS
Supporting information Section 1 details a literature search on the use of azithromycin MDA in humanitarian settings. Section 2 details the search used in ClinicalTrials.gov to identify clinical trials relevant to azithromycin MDA. Section 3 details the conversion from a per live-birth mortality rate to per-person-time. Section 4 gives the calculations for estimating the number of crises exceeding a given mortality threshold.
Open in Who Shared Issue with article?

Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic - Nature Communications

|
By Charles A. Whittaker, Gregory Barnsley, Daniela Olivera Mesa, Victoria Cox, Daniel Laydon, Feng Zhu, Patrick Doohan, Lilith K. Whittles, Peter Winskill, Arminder Deol, Katharina Hauck, Lin-Fa Wang, Oliver Watson
| Nature Verified
Abstract COVID-19 has underscored the need for more timely access to vaccines during future pandemics. This has motivated development of broad-spectrum vaccines providing protection against entire viral families, which could be stockpiled and deployed rapidly following detection.
Open in Who Shared Issue with article?

Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic

|
By Charles A. Whittaker, Gregory Barnsley, Daniela Olivera Mesa, Daniel Laydon
| medRxiv
The Coalition for Epidemic Preparedness Innovations (CEPI) funded the investigation into the impact of the 100 Days Mission. Authors maintained full freedom when designing the study and deciding on additional scenarios to explore. ACG has received personal consultancy fees from HSBC, GlaxoSmithKline, Sanofi and WHO related to COVID-19 epidemiology and from The Global Fund to Fight AIDS, Tuberculosis and Malaria for work unrelated to COVID-19.
Open in Who Shared Issue with article?
See all 8 articles